New bivalent polio vaccine playing key role in global polio eradication

Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial

A child is immunized in Jalalabad, eastern Afghanistan on a memorable day for polio eradication: 16 December 2009, the first day the groundbreaking bivalent oral polio vaccine was ever used. Cornelia Walther/UNICEF

A head to head trial against current poliovirus vaccines has found that the new bivalent oral vaccine against poliovirus, which targets both the remaining types of poliovirus concurrently, induces a stronger immune response than the traditional trivalent vaccine and a similar immune response to the latest monovalent (monovalent type 1 or monovalent type 3)  vaccines. Furthermore, it is easier to administer, allowing children to be immunised against the two remaining types of wild poliovirus in a single oral dose. These are the conclusions of an Article published Online First in The Lancet.

For details, please go to:
http://www.thelancet.com


Related News

   16/10/2018
Over 31 million children will be vaccinated against measles in Pakistan in a countrywide immunization campaign supported by the polio programme’s greatest asset: its people.
   08/10/2018
Group continues its historical support
   05/10/2018
Special report on Papua New Guinea
   28/09/2018
Head of WHO Chad Dr Jean-Bosco Ndihokubwayo speaks about the ongoing efforts to reach every child with polio vaccine across Chad
   26/09/2018
The last man with smallpox was an advocate for polio eradication.
   21/09/2018
Girl or boy, health workers in Nigeria are determined to show parents that the polio vaccination is for all children.